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We evaluated the eﬀect of kigikenchuto (KKT), a traditional Japanese formula, in a modiﬁed rat pressure-loading skin ulcer
model. Rats were divided into three groups, KKT extract orallyadministered (250 or500mg/kg/dayfor 35 days) andcontrol. KKT
shortened the duration until healing.Immunohistochemically,KKT increased CD-31-positive vessels in early phase and increased
α-smooth muscle actin-(α-SMA-) positive ﬁbroblastic cells in early phase and decreased them in late phase of wound healing.
By Western blotting, KKT showed the potential to decrease inﬂammatory cytokines (MCP-1, IL-1β,a n dT N F - α) in early phase,
decrease vascularendothelialgrowthfactorinearlyphaseandincreaseitinlatephase,andmodulatetheexpressionofextracellular
protein matrix (α-SMA, TGF-β1, bFGF, collagen III, and collagen I). These results suggested the possibility that KKT accelerates
pressureulcer healingthroughdecreases ofinﬂammatorycytokines,increaseofangiogenesis,andinductionofextracellular matrix
remodeling.
1.Introduction
Japan is now on its way to becoming an aging society, a
situation also seen in other advanced countries. In these
aging societies, geriatric diseases are necessarily receiving
moreandmoreattention,andoneofsuchdiseasesispressure
ulcer(decubitus)[1, 2]. This disease has a decidedly negative
impact on the quality of life. Its cause is the continuation
of pressure against subcutaneous soft tissue, and external
factors such as shear stress, tissue deformation, temperature,
and humidity, play important roles in its generation [3–5].
Pressure ulcers are classiﬁed into two types, shallow ulcer,
characterized by damage to the dermis, and deep ulcer, with
damage through subcutaneous tissue. The latter is more dif-
ﬁculttotreatcomparedtotheformer,andeﬀectivetreatment
for it has been awaited. Deep ulcer is deﬁned as ulcerextend-
ing through the skin surface layer to deeper tissue. Accord-
ing to the grade classiﬁcation of the European Pressure
Ulcer Advisory Panel, grade III is damage to subcutaneous
tissue, and grade IV is damage reaching to muscle or bone
[6].
Recently, a new pressure ulcer animal model utilizing
magnetic compression was developed, with focus on ische-
mia-reperfusion injury for the formation of skin ulcerations
[7, 8], and it has been used for understanding the role of
ischemia-reperfusion injury intheskin[9–11].However,this
pressure ulcer animal model with magnet is not appropriate
for animal models of severe pressure ulcer, because pro-
longed compression by magnet inﬂuences only the superﬁ-
cial skin but not deep muscle. Thus, to create severe pressure
ulcers, various kinds of original devices have been developed
as pressure indenters [12–14], but their manufacturing is
not easy and their production costs are high. Then, in their
stead,asimplepressureloadingmethodusingastainlesssteel
cylinder for 24 hours has been applied for the purpose of
therapeuticdrugdevelopmentforseverepressureulcers[15].
Cellgrowthfactorsandangiogenesisfactorsareresponsi-
bleforthe healing processofpressure ulcersas well as wound2 Evidence-Based Complementary and Alternative Medicine
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Figure 1: 3D-HPLC proﬁle of kigikenchuto. The peaks of guiding compounds included in each crude-drug component of kigikenchuto—
paeoniﬂorin, cinnamic acid, cinnamaldehyde, astragaloside IV, glycyrrhizin, 6-gingerol, ligustilide, and so forth,—are presented.
healing, and they are divided into three main overlapping
phases—inﬂammation, granulation tissue formation, and
matrix formation and remodeling [16, 17]. The chronic
wound is associated with increased inﬁltration of inﬂam-
matory cells, decreased production of cytokines responsible
for angiogenesis, poor granulation, keloid formation due to
reduced or excess accumulation of extracellular matrix, and
delayed new skin formation.
For the treatment of pressure ulcers, growth factor prod-
ucts are clinically applied externally [18–21], and for oral
administration there are a few supplements such as zinc
preparation, vitamin C, and arginine [22–24]. In recent
years, traditional Japanese (Kampo) medicines have been
used for the treatment of various kinds of diseases. Clinical
reports regarding Kampo medicines for the treatment of
pressure ulcers have been published, and we also reported
that elderly patients were successfully treated with a Kampo
formula, kigikenchuto (KKT) [25, 26]. KKT is a formula
created originally by a Japanese medical doctor, Seishu
Hanaoka (1760–1835),andithasbeenusedforthetreatment
of intractable skin ulcer, like pressure ulcer, in Japan.
However,theactivemechanism ofKKTonpressure ulcerhas
not been clariﬁed. The purpose of this study is to evaluate
the eﬃcacy of KKT on pressure ulcer by using a modiﬁed
pressure-loading skin ulcer model of rats [15]a n da l s ot o
clarify its active mechanism by immunohistochemical and
Western blot analyses.
2.Materialsand Methods
2.1. Preparation of Extract. Seven crude drugs composing
KKT, Cinnamomi Cortex (Cinnamomum cassia Blume),
Paeoniae Radix (Paeonia lactiﬂora Pallas), Zingiberis Rhi-
zoma (Zingiber oﬃcinale Roscoe), Zizyphi Fructus (Zizy-
phus jujuba var. inermis Rehder), Glycyrrhizae Radix (Gly-
cyrrhiza glabra Fischer), Angelicae Radix (Angelica acutiloba
Kitagawa), and Astragali Radix (Astragalus membranaceus
Bunge), were purchased from Tochimoto Tenkaido Co. Ltd.
(Osaka,Japan),andmixedataratioof4:6:1:4:2:4:4.The
extractwaspreparedbyboilingamixture(100g)oftheabove
crude drugs gently in 500ml of water for 50min and then
ﬁltrating the decoction. The ﬁltrate was concentrated under
reducing pressure, resulting in a yield of 20.4% by weight of
the original preparation.
A three-dimensional high performance liquid chro-
matography (3D-HPLC) proﬁle of KKT extract is shown
in Figure 1. The high performance liquid chromatography
(HPLC) conditions were as follows: KKT extract (0.2g) was
dissolvedin2ml70%acetonitrileunderultrasonication.The
solution was ﬁltered with membrane ﬁlter (0.45μmp o r eEvidence-Based Complementary and Alternative Medicine 3
size; Millipore Corp., Billerica, Mass) prior to injection. The
HPLC apparatuswas a SD-8020system (TosohCorp., Tokyo,
Japan) consisting of a CCPM-II multisolvent delivery pump
and a PD-8020 photodiode array detector. A TSK gel ODS-
80TS column (4.6 × 150mm i.d., 5μm, Tosoh Corp.) was
used for analysis. The gradient elution was in accordance
with that reported previously [27]. Brieﬂy, the mobile phase
consistedof(A)0.017%phosphoricacidand(B)acetonitrile.
The gradient elution was programmed as follows: 0–5min,
18–20% B; 5–9min, 20–25% B; 9–15min, 25–29% B; 15–
18min, 29-29% B; 18–26min, 39–43% B; 26–34min, 43–
65% B; 34–40min, 65-65% B. The other analysis conditions
were as follows: ﬂow rate, 1.0ml/min; injection volume,
10μl; UV scan 200–300nm.
2.2. Animals and Pressure-Loading Skin Ulcer. Wistar rats
weighing 410–480g were purchased at 23 weeks of age from
Japan SLC, Inc. (Shizuoka, Japan) and were kept in an
automaticallycontrolled room (temperatureabout24◦Ca n d
humidity about 60%) with a conventional dark/light cycle.
The animals were allowed free access to standard laboratory
food. All experimentation was performed in accordance
with the Guide Principles for the Care and Use of Labo-
ratory Animals approved by the Japanese Pharmacological
Society and also approved by the Committee on Animal
Experimentation, University of Toyama (no. S-2010 INM-
4).
In this study we adopted a pressure ulcer model of rats
[15] using our original modiﬁcation. After test-keeping for
oneweek,hairfromtherightgreatertrochanteroftheratwas
extensively removed using electric hair clippers and an elec-
tric shaver. Foranesthesia, sodium pentobarbital at 50mg/kg
was intraperitoneally administered. Before pressure loading,
rats assigned to this purpose were anesthetized, and mainte-
nance doses of 40mg/kg were given at 1h 15min and again
at 3h later. If necessary, additional anesthesia (40mg/kg)
was given during pressure loading. The anesthetized rats
were ﬁxed in a lateral position on a wooden ﬁxation plate.
As a cushion, a piece of absorbent cotton was placed
between the femoral region and the ﬁxation plate, and a
stainless steel cylinder weighing 1.02–1.03kg and measuring
19mm and 50cm in diameter and length, respectively,
with a silicon stopper measuring 10mm in diameter, was
placed on the skin of the right greater trochanter (1.30 to
1.31kg/cm2)( Figure 2). The duration of pressure loading
was 6h, and pressure loading was performed daily for 4
days.
2.3. Grouping and Drug Treatment. Rats that had been
subjected to pressure loading for 4 days were divided into
three groups, the low-dose KKT extract (250mg/kg/day)
administered group (LD-KKT), the high-dose KKT extract
(500mg/kg/day) administered group (HD-KKT), and the
water-only administered group (controlgroup). KKTextract
was dissolved in 2ml of water and administered orally
through a stomach tube daily for 35 days from the last
pressure-loading day. The day when pressure loading was
completed was deﬁned as day 0, the next day 1, and so forth.
Figure 2: Photograph of pressure loading. The anesthetized rats
were ﬁxed in a lateral position on a wooden ﬁxation plate. As a
cushion,apiece ofabsorbentcottonwasplacedbetween thefemoral
region and the ﬁxation plate, and a stainless steel cylinder weighing
1.02–1.03kg and measuring 19mm and 50cm in diameter and
length, respectively, with a silicon stopper measuring 10mm in
diameter, wasplacedontheskinoftherightgreatertrochanter(1.30
to 1.31kg/cm2).
2.4. Macroscopic Observation of Pressure Ulcer. Eighteen rats,
six ratsper group,were used. A picture ofpressure ulcerwith
a caliper square and a color scale was taken daily from day
0 to day 35 by electronic camera, Optio750Z (HOYA Corp.,
Tokyo, Japan). The distance between the camera and skin
ulcer was ﬁxed at 23cm. After the color image was com-
pensated based on a standard gray of color scale by the use
of Color Dial Photo 3 (Mitsubishi Electric Micro-Computer
Application Software Co., Ltd., Amagasaki, Japan), the size
of the ulcer image data was uniﬁed. The pressure ulcer
area was calculated by image analysis software, VH Analyzer
(Keyence Corp., Osaka, Japan), and the pressure ulcer area
ratio,percentageofulcerareaofeachdaytothatofday0,was
calculated. Healing of ulcer was deﬁned as when the image
analysis software could not detect ulcer.
2.5. Histopathological and Immunohistochemical Analysis.
Eighty-four rats, seven at each evaluation day in each group,
were used. At each evaluation day, rats were euthanized
under anesthesia and skin ulcer areas (2.5 × 2.5cm) were
excised. Samples of skin were cut out from the head side to
the tail side. Half amounts of skin ulcer tissues from days 3,
7, 14, and 35 were ﬁxed in 4% paraformaldehyde, processed
routinely, and embedded in paraﬃn. Five-μm sections were
conventionally stained with hematoxylin-eosin (HE). The
paraﬃn-embedded specimens were deparaﬃnized in xylene
a n dd e h y d r a t e dw i t he t h a n o l .K N 9w a su s e df o ra n t i g e n
retrieval (95◦C, 40min, Pathology Institute, Toyama, Japan),
and endogenous peroxidase was blocked with 3% hydrogen
peroxide (Kanto Chemical Industry Co., Ltd., Tokyo, Japan)
for 10min at room temperature, and then washed with
distilled water and TBS. Nonspeciﬁc binding was blocked by
treatment with a special blocking reagent (Dako Cytomation
Co., Glostrup, Denmark) for 15min. Anti VEGF (1:40;
Immuno-Biological Laboratories Co., Ltd., Fujioka, Japan)4 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Typical macroscopic view of pressure ulcer of control
group on days 1, 7, 14, 21, 28, and 35. Pressure-loaded portion
became necrotic after release of loading (day 1), and crust was
formed in the ulcer site with redness of surrounding skin (day
7). Size of ulcer gradually decreased (days 14, 21, and 28), and
disappeared (day 35).
[28], α-SMA (1:100; DAKO Cytomation) [29], or CD-31
(1:100; Santa Cruz Biotechnology Inc., CA) [30]a n t i b o d y
was applied, and the sections were then incubated in a
moist box for 30min. After washing the specimens with
TBS, they were then stained using a commercial kit (Chem-
Mate EnVision Detection System Peroxidase/HRP; DAKO
Cytomation). After counterstaining by hematoxylin, sections
were rinsed, dehydrated, and covered. All image data of
the specimens were loaded and analyzed by image analysis
software, Virtual Slide System Ver.2.1 (Olympus Co., Tokyo,
Japan).
The CD-31-positive vessels were evaluated at the ulcer
site, ulcer edge, and granulation tissue (×200) per specimen,
and expressed as the number of blood vessels per ﬁeld.
VEGF-positive cells were evaluated with Virtual Slide System
Ver.2.1 (×200; Olympus). α-SMA-positive areas were evalu-
ated by image analysis software at the ulcer site, ulcer edge,
and granulation tissue (×100) per specimen and expressed
as the area per ﬁeld.
2.6. Protein Preparation and Western Blotting. We exam-
ined the protein expression of inﬂammatory cytokines—
monocyte chemotactic protein-1 (MCP-1), interleukin-1β
(IL-1β), and tumor necrosis factor-α (TNF-α), angiogenesis
growth factors; vascular endothelial growth factor (VEGF)
and platelet derived growth factor (PDGF), and extracellular
matrix remodeling factors; α-smooth muscle actin (α-SMA),
transforming growth factor-β1( T G F - β1), basic ﬁbroblast
growth factor (bFGF), collagen III, and collagen I, in the
area between the surface skin of the wound and the fascia
of hamstring muscles by Western blotting. Skin tissues of
the ulcer portion at days 3, 7, 14, and 35 were, respectively,
homogenized in lysis buﬀer[137mM NaCl,20mM Tris-HCl
(pH 7.5), 1% polyoxyethylene octylphenyl ether (NP-40),
10% glycerol, 1mM phenylmethylsulfonyl ﬂuoride (PMSF),
Protease Inhibitor Complete Mini (F-Hoﬀman-La Roche,
Basel,Switzerland)]byusingKinemachikaPolytronHomog-
enizer PT20SKR (Kinemachika AG, Lucerne, Switzerland).
The lysates were prepared by centrifugation at 5,500rpm for
10 min at 4◦C, and the supernatants were collected. The
concentration of protein in the supernatants was detected
by Protein Assay Kit (Bio-Rad Laboratories, Hertfordshire,
UK), reduced to 1μg/μl with sodium dodecyl sulfate (SDS)
sample buﬀer and distilled water, and then the sample was
boiled for 4min at 95◦C. The samples were separated by
12% SDS-polyacrylamide gel electrophoresis and transferred
to poly vinylidene diﬂuoride (PVDF) membranes (Millipore
Corp.). The membrane was treated with 5% skim milk
with PBS-T for 1h at room temperature, reacted with
primary antibodies for Western blottinganalysis overnightat
4◦C, including MCP-1 (1:1000; Santa Cruz Biotechnology
Inc.), IL-1β (1:1000; Santa Cruz Biotechnology Inc.),
TNF-α (1:1000; R&D Systems Inc., MN), VEGF (1:1000;
Immuno-Biological Laboratories Co., Ltd., Gumma, Japan),
PDGF (1:1000; Santa Cruz Biotechnology Inc.), α-SMA
(1:1000; DAKO Cytomation Colorado Inc. Co., CO), TGF-
β1 (1:1000; Santa Cruz Biotechnology Inc.), bFGF (1:500;
Wako Pure Chemical Industries, Osaka, Japan), collagen
III (1:1000; Santa Cruz Biotechnology Inc.), and colla-
gen I (1:1000; Santa Cruz Biotechnology Inc.). β-actin
(Abcam, Cambridge, UK) was used as internal control.
The antibodies were detected using horseradish peroxidase-
conjugated anti-mouse, or anti-rabbit IgG (GE Healthcare
UK, Buckingham, UK) for 1h at room temperature and
visualized by ECL Western blotting detection reagent (GE
Healthcare) on X-ray ﬁlm (RX-U. Fuji Safelight Glass
No. 8U: Fujiﬁlm, Tokyo, Japan) and determined quantity
by Image J 1.34s software (National Institutes of Health,
USA).
2.7. Statistical Analysis. All values were presented as mean
± SE. One-way analysis of variance (ANOVA) followed by
Dunnett’s test was used to determine the diﬀerences among
groups on the assessments of ulcerated area, histological
ﬁndings, and Western blotting. P<. 05 was accepted as
statistically signiﬁcant. Statistical analyses were carried out
using JMP 8.0 (SAS Institute, Cary, NC).
3.Results
3.1. Macroscopic and Histopathological Findings. Immedi-
ately after completion of pressure loading, the skin surface
was depressed and partially colored brown or white. After
day 1 the pressure-loading portion became necrotic, and the
skin surrounding the ulcer edge turned red and a crust was
formed at the ulcersite. Gradually the skin ulcerdecreased in
size and then disappeared (Figure 3).
The areas of pressure ulcers of the control, LD-KKT, and
HD-KKT groups were evaluated each day. Those of the LD-
KKTandHD-KKTgroupsonday1weresigniﬁcantlysmaller
than that of control, and there was no signiﬁcant diﬀerence
among them on days 2 to 9. On day 10, days 12 to 16,Evidence-Based Complementary and Alternative Medicine 5
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Figure4:Timecoursesoftheareasofpressureulcers.Closedcircles
show the area of skin ulcer of control group, open triangles show
that of the LD-KKT group, and open circles show that of the HD-
KKT group. The areas of skin ulcers of the LD-KKT and HD-KKT
groups were smaller than that of the control group on day 1, and
there was no diﬀerence among the three groups on days 2 to 9. On
day 10, days 12 to 16, and days 18 to 24, the areas of skin ulcers
of the LD-KKT and HD-KKT groups were smaller than that of the
control group. Valuesare expressed as mean ±SE (n = 6). ∗P<. 05.
∗∗P<. 01 versus control.
and days 18 to 24, the areas of the skin ulcers of the LD-
KKT and HD-KKT groups were signiﬁcantly smaller than
that of the control group (Figure 4). The number of days
until disappearance of skin ulcer in the control group was
26.67 ± 0.42 days, and those of the LD-KKT group (23.50
± 3.35 days, P<. 05) and HD-KKT group (22.33 ± 0.67
days, P<. 01) were signiﬁcantly shortened compared to the
control group.
Histopathological ﬁndings of skin ulcer are shown in
Figure 5. The base of skin ulcer was ﬁlled with a necrotic
layer composed of ﬁbrin and necrotic tissue. Although
subcutaneousstructureswereviable,cutaneousmuscleswere
broken and vessels lapsed into ﬁbrinoid necrosis. Epidermal
cells spread out from the ulcer edge to the ulcer site over
time, and all ulcers disappeared by day 35. Epidermal cells
of ulcer scar showed characteristics of a stratiﬁed squamous
epithelium and then disappeared by day 35.
3.2. Immunohistochemical Findings
3.2.1. CD-31. Positive reactions to anti-CD-31 antibody
were observed at the ulcer edge and just below the part of
pressure loading. At the ulcer edge, CD-31-positive vessels
were observed in all groups after day 3, and more CD-
31-positive vessels were seen in the LD-KKT and HD-KKT
groups than in the control group. The numbers of CD-31-
positivevesselsofday7demonstratedanincreasing tendency
compared to those of day 3 in each group, and a lot of
small vessels were seen on day 7. By day 14, the numbers of
CD-31-positive vessels had decreased in all groups and then
Day 3
Day 7
Day 14
Day 35
Figure 5: Histopathological ﬁndings of pressure ulcer. Typical
microscopic views of HE stain of skin ulcer in the control group
on days 3, 7, 14, and 35 are shown(scale bar, 2mm).
decreased further by day 35, becoming equal to normal skin
not having undergone pressure loading (Figure 6(a)). The
number of CD-31 immunopositive vessels per ﬁeld (×200)
was counted in the area of damaged tissue (ulcer site, ulcer
edge, and granulation tissue), and on days 3 and 7 those of
the LD-KKT and HD-KKT groups increased compared to
that of the control group (Figure 6(b)).
3.2.2. VEGF. On day 3, positive reaction to anti-VEGF anti-
body was observed at the ulcer edge. The necrotic layer,
granulation layer, and subcutaneous tissue of the central
area showed negative reaction to anti-VEGF antibody, and
there was no particular diﬀerence among the three groups.
On day 14, numerous VEGF immunopositive cells were
observed in the granulation tissue of all groups, and in
KKT-administered groups more VEGF immunopositive cells
were seen compared to the control group (Figure 7). On
day 35, VEGF-positive cells were still observed in KKT-
administered rats, but had almost disappeared in control
rats.
3.2.3. α-SMA. Positive reactions to anti-α-SMA antibody
were observed at the ulceredge and just below the portion of
pressure loading. At the ulcer edge, vascular smooth muscle6 Evidence-Based Complementary and Alternative Medicine
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Figure 6: CD-31 immunohistochemical ﬁndings of vessels at pressure ulcer edge on days 3, 7, 14, and 35. CD-31 immunopositive vessels
are stained brown ((a); scale bar, 100μm). The numbers of CD-31 immunopositive vessels per ﬁeld (×200) were counted at wound tissue
area including ulcer site, ulcer edge and granulation tissue (b). Values are expressed as mean ± SE (n = 4–7). ∗P<. 05, ∗∗P<. 01, versus
control.
cells showed positive reaction to anti-α-SMA antibody in all
groups from day 3. On day 7, positive reaction to anti-α-
SMA was observed not only at vascular smooth muscle cells
of subcutaneous tissue but also at myoﬁbroblasts around
granulated areas in connective tissue. On day 14, more α-
SMA-positive myoﬁbroblasts were seen in connective tissue,
butonday 35 their number had decreased (Figure 8(a)). The
images of stained whole ﬁelds of injured tissue, from the
epidermis to the fascia of the hamstring, were scanned into
the computer system, and the area of the positive reaction
to anti-α-SMA antibody was measured by image analysis
software. The average of the area of the positive reaction
to anti-α-SMA antibody was calculated. The result showed
that, on day 3, the area of the positive reaction to anti-
α-SMA antibody in the HD-KKT group was signiﬁcantly
higher compared to control, on day 14 that of each group
reached apeak, and on day35those in theLD-KKTand HD-
KKT groups signiﬁcantly decreased compared to that in the
control group (Figure 8(b)).
3.3. Protein Levels by Western Blotting. Inﬂammatory cy-
tokines: the protein levels of MCP-1 of the LD-KKT and
HD-KKT groups were signiﬁcantly lower than that the
control group on day 3 (Figure 9(a)). The value of IL-
1β in the HD-KKT group was signiﬁcantly suppressed on
days 3 and 7 compared to control (Figure 9(b)). TNF-α ofEvidence-Based Complementary and Alternative Medicine 7
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Figure 7: VEGF immunopositive area at pressure ulcer edge (days 3 and 14; scale bar, 100μm). On day 3, VEGF immunopositive cells
were mainly endothelial cells. On day 14, the LD-KKT and HD-KKT groups had more VEGF immunopositive ﬁbroblasts than the control
group.
the HD-KKT group was also signiﬁcantly decreased com-
pared to control on days 3 and 7 (Figure 9(c)).
Angiogenesisgrowthfactor: theproteinlevelsofVEGFin
the LD-KKT and HD-KKT groups were signiﬁcantly lower
than that of control on days 3 and 7, and that of the HD-
KKT group was higher than that of control on days 14 and
35 (Figure 10(a)). PDGF of the HD-KKT group signiﬁcantly
increased comparedtothatofcontrolonday3anddecreased
compared to that of control on day 7 (Figure 10(b)).
Extracellular matrix protein: the protein level of α-
SMA of the HD-KKT group increased on day 3 and those
of the LD-KKT and HD-KKT groups decreased on day
35 compared of that of the control group with statistical
signiﬁcance (Figure 11(a)).The valuesof TGF-β1i nt h eH D -
KKT group on days 3 and 14 were signiﬁcantly higher than
that ofcontrol (Figure 11(b)). The valuesofbFGF in theLD-
KKT and HD-KKT groups were signiﬁcantly lower than that
of control on day 7, and that of the HD-KKT group was
higher than that of control on day 35 (Figure 11(c)). The
protein levels of collagen III of the LD-KKT and HD-KKT
groups were signiﬁcantly higher than that of control on day
3( Figure 11(d)). The protein level of collagen I of the LD-
KKT group on day 7 and that of the HD-KKT group on day
35 were signiﬁcantly elevated compared to those of control
(Figure 11(e)).
4.Discussion
In the present study, we evaluated the eﬀect of a Kampo
formula, KKT, by a modiﬁed pressure ulcer rat model using
a stainless steel cylinder. As a result, we clariﬁed that KKT
had a healing acceleration eﬀect on pressure ulcer and some
of its mechanism(s). By the previously reported method,
rats under anesthesia received a heavy load for 24h [15],
but our modiﬁed method was able to develop pressure ulcer
constantly with a relatively light load of pressure for 6h daily
for 4 days.
In the present study, ﬁrstly from a macroscopic perspec-
tive, the number of days required for healing of pressure
ulcer in KKT-administered groups was less than that of
control. Further, we focused on the inﬂammatory phase, the
early phase of wound healing, and analyzed inﬂammatory
cell inﬁltration, but we could not ﬁnd clear diﬀerence
between KKT-administered rats and control rats in terms of
pathological ﬁndings. We evaluated the protein expression
of inﬂammatory cytokines such as MCP-1, IL-1β,a n d
TNF-α by Western blotting, and we found that those in
the KKT-administered groups were lower than that of
control on days 3 and 7 in the early phase as a whole.
It is known that the expression of inﬂammatory cytokines
increases during the course of chronic wound [31, 32],
so the possibility is suggested that KKT accelerates healing
of pressure ulcer through the suppression of inﬂammatory
cytokines.
Next, we evaluated angiogenesis of the portion of pres-
sure loading. By immunohistochemical examination, the
number of vessels counted by using anti-CD-31 antibody,
which labels vascular endothelial cells, was increased on days
3 and 7, so it is considered that KKT might increase angio-
genesis in early phase. Further, anti-VEGF antibody-positive8 Evidence-Based Complementary and Alternative Medicine
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Figure 8: α-SMA immunohistochemical ﬁndings on days 3, 7, 14, and 35. α-SMA immunopositive cells in skin ulcer site are shown ((a);
scale bar, 100μm). The numbers of α-SMA immunopositive cells per ﬁeld were counted in the damaged area including ulcer site, ulcer edge
and granulation tissue (b). All values are presented as mean ± SE (n = 4–7). ∗P<. 05. ∗∗P<. 01 versus control.Evidence-Based Complementary and Alternative Medicine 9
ab cabc abc ab c
∗∗
∗∗
Day 35 Day 14 Day 7 Day 3
0
1
2
3
M
C
P
-
1
/
β
-
a
c
t
i
n
r
a
t
i
o
Day 35 Day 14 Day 7 Day 3
MCP-1
β-actin
(a)
ab cabc abc ab c
∗
∗
Day 35 Day 14 Day 7 Day 3
0
1
2
3
4
I
L
-
1
β
/
β
-
a
c
t
i
n
r
a
t
i
o
Day 35 Day 14 Day 7 Day 3
IL-1β
β-actin
(b)
ab cabc abc ab c
∗∗ ∗∗
Day 35 Day 14 Day 7 Day 3
0
1
2
3
T
N
F
-
α
/
β
-
a
c
t
i
n
r
a
t
i
o
Day 35 Day 14 Day 7 Day 3
TNF-α
β-actin
Control
LD-KKT
HD-KKT
(c)
Figure 9: Expressions of inﬂammatory cytokines in skin tissue of pressure ulcer on days 3, 7, 14, and 35 as examined by Western Blotting.
(a) MCP-1, (b) IL-1β,( c )T N F - α.V a l u e sa r ee x p r e s s e da sm e a n± SE (n = 4–7). ∗P<. 05, ∗∗P<. 01 versus control.
cells, which were mainly ﬁbroblastic cells, were increased
in KKT-administered rats compared to control especially
on day 14. It is reported that VEGF promotes the increase
of vascular permeability, angiogenesis, and storage of col-
lagen, expresses highly under ischemic condition, and its
peak is 3 to 7 days after wound injury [33]. In this
study, the expression levels of VEGF were depressed in
early phase (days 3 and 7) and elevated in late phase
(days 14 and 35) in KKT-treated rats, and the level of
PDGF, another angiogenesis factor, in the HD-KKT group
i n c r e a s e do nd a y3a n dd e c r e a s e do nd a y7c o m p a r e dt o
control. These variations of angiogenesis factors with the
time course might be related to the acceleration of wound
healing.
The area of the positive reaction to anti-α-SMA anti-
body was assessed immunohistochemically to evaluate the
accumulation of extracellular matrix. The area in the HD-
KKT group in early phase was higher and that in late phase
was lower compared to control. The protein expression of α-
SMA showed similar ﬁndings to the histological study. The
protein expression of TGF-β1, which is responsible for the
phenotypic change from ﬁbroblast to myoﬁbroblast [34],
was elevated on days 3 and 14. These results suggested the
possibility that KKT induces TGF-β1 to transform from10 Evidence-Based Complementary and Alternative Medicine
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Figure 10:Expressionsofangiogenesisgrowth factors inskintissue
of pressure ulcer on days 3, 7, 14, and 35 as examined by Western
Blotting. (a) VEGF, (b) PDGF. Values are expressed as mean ± SE
(n = 4–7). ∗P<. 05, ∗∗P<. 01 versus control.
ﬁbroblast to myoﬁbroblast in the ulceration phase, and
facilitates smooth restructuring of extracellular matrix in the
tissue-remodeling phase.
The protein expression of bFGF in the HD-KKT group
was increased on day 35 in late phase. In this immuno-
histochemical study, the areas of the positive reaction to
anti-α-SMA antibody in the KKT-administered groups were
decreased on day 35. It is reported that bFGF inhibits the
abnormal remodeling of extracellular matrix and is involved
in the improvement of qualitative healing of wound by
the induction of myoﬁbroblast apoptosis [35–37]. There-
f o r e ,i ti sc o n s i d e r e dt h a tK K Tm i g h th a v es t i m u l a t e dt h e
transformation from ﬁbroblast to myoﬁbroblast in the early
s t a g eo ft h eu l c e r a t i o np h a s et h r o u g hi n c r e a s i n gt h ep r o t e i n
level of TGF-β1 and might be associated with apoptosis
of myoﬁbroblast through the subsequent increase of the
protein level of bFGF in late phase, then enhancing the
remodeling of extracellular matrix. However, the mecha-
nism of the increasing TGF-β1 and bFGF by KKT is not
clear. These are the challenges to be addressed in future
studies.
As for extracellular protein, it is well known that col-
lage III, reticular ﬁber, is produced with destruction of
collagenous tissue and is replaced by collagen I, which
gradually develops thick ﬁber [38]. In this study of KKT
administration, the protein expression of collagen III was
increased on day 3 in early phase, and that of collagen I was
increased on day 35 in late phase. These results suggested the
possibility that the increases of extracellular matrix proteins
are associated with some of the mechanism(s) of the wound
healing acceleration eﬀect of KKT. In recent years, high-
quality wound healing, in addition to fast healing, has been
urgently needed from the treatment of pressure ulcer or skin
ulcer [39]. It was reported that remodeling of extracellular
matrix of acute wound required one to twelve months
[40]. In the future, it will be necessary to demonstrate the
histological ﬁndings after healing of skin ulcer by treatment
with KKT.
Although the wound healing acceleration eﬀects of each
crude drug composing KKT and their representative com-
pounds were not evaluated in this study, Paeoniae Radix
showed wound healing acceleration eﬀect in the in vivo
experiment [41]. Additionally, it was also reported that the
waterextractsofAngelicaeRadixandAstragaliRadixshowed
angiogenic eﬀects in the in vitro experiments through phos-
phorylation of p38 or JNK1/2 and VEGF-KDR/Flk pathway
or P13K-Akt-eNOS pathway, respectively [42, 43]. It will
be necessary to demonstrate the eﬀects of each crude-drug
component or active constituent in the future, as the eﬀects
of these crude-drug components might have been involved
in the shortening eﬀect of KKT on healing of pressure
ulcer.
5.Conclusion
In the present study, the eﬀects and the mechanism(s) of
KKT,a traditional Japanese formula, were evaluatedby using
modiﬁed pressure-loading skin ulcer model of rats. The
resultsrevealedthatKKTexertsawoundhealingacceleration
eﬀect. Further, the possibility was raised that the eﬀect of
KKTmightbeassociatedwithadecreaseincertaincytokines,
which are expressed in the inﬂammation phase of skin
ulcer, increase ofangiogenesis, and induction ofextracellular
matrix remodeling.Evidence-Based Complementary and Alternative Medicine 11
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Figure 11: Expressions of extracellular matrix remodeling factors in skin tissue of pressure ulcer on days 3, 7, 14, and 35 as examined by
Western Blotting. (a): α−SMA, (b): TGF-β1, (c): bFGF, (d): collagen III, (e): collagen I. Values are expressed as mean ± SE (n = 4–7).
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